MILAN, Dec. 5, 2022 /PRNewswire/ -- Bracco Diagnostics Inc., a U.S. subsidiary of Bracco Imaging S.p.A., one of the world's leading companies in the diagnostic imaging business, announced over half (53%) of radiology professionals have seen an increase in MRI procedures over the last year and another one in two (55%) have concerns about the availability of gadolinium-based contrast agents (GBCAs) for use in magnetic resonance imaging (MRI) procedures. These topline findings come from a national quantitative survey, commissioned by Bracco in collaboration with Sermo, a global medical research company, that delve into the perspectives and expectations of 200 radiology professionals, with a specific focus on MRI contrast agents.
The shortage of iodinated contrast for computed tomography scans in early 2022 may be one aspect fueling concerns over supply chain disruptions. Radiologists in small hospitals express the highest level of concern (75%) about the availability of gadolinium-based contrast agents compared to 35% from radiologists at larger institutions. The survey also finds that 63% of radiologists believe it is important for contrast agents to be manufactured in the U.S, with 88% explaining products manufactured in the U.S. – through closed supply chains – are one option to lessen concerns about availability.
When asked to rank factors critical to the success of their radiology practices, professionals listed supply availability (87%), image quality (92%), and patient safety (93%) above other options such as revenue generation, staff training, and sustainable practices.
For those who need to move fast and expand clinical capabilities -- and would love new equipment -- the uCT 550 Advance offers a new fully configured 80-slice CT in up to 2 weeks with routine maintenance and parts and Software Upgrades for Life™ included.
"We are continually listening to and value the needs of radiologists," said Cosimo De Pinto, Senior Vice President of Sales and Marketing at Bracco Diagnostics Inc. The results of this survey mirror what we have been hearing from our customers: HCPs are concerned about the availability and supply of contrast media, a key part of the diagnostic process. That is one of the key reasons we made a strategic, global collaboration with Guerbet in both research, development, and manufacturing of VUEWAY injection. This strategic collaboration will expand access to this important new contrast agent which has the potential to help improve diagnoses and ultimately improve patient care."
An astonishing 99% of radiologists confirm they are interested in using an MRI contrast agent that contains half the amount of gadolinium with the breakdown being 60% very interested and 39% somewhat interested.